Syngen BiotechLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Syngen BiotechLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth47.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Mar 25
Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?

Feb 25
Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?

Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?

Feb 04
Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 14
Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16
Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Nov 25
Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Syngen BiotechLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:8279 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20241,916237278372N/A
3/31/20241,861262261354N/A
12/31/20231,837275321415N/A
9/30/20231,890287294363N/A
6/30/20231,961308287370N/A
3/31/20231,996329-237354N/A
12/31/20221,931321-307277N/A
9/30/20221,848319-258328N/A
6/30/20221,655296-294279N/A
3/31/20221,545262226300N/A
12/31/20211,471238275336N/A
9/30/20211,372212287357N/A
6/30/20211,36320377251N/A
3/31/20211,34921776283N/A
12/31/20201,311216-53220N/A
9/30/20201,310225-138147N/A
6/30/20201,317211-18172N/A
3/31/20201,301195-5145N/A
12/31/20191,297189148255N/A
9/30/20191,281181124211N/A
6/30/20191,24218484171N/A
3/31/20191,15215355129N/A
12/31/20181,080134-2767N/A
9/30/2018997116-2074N/A
6/30/2018959126-3089N/A
3/31/2018944143N/A197N/A
12/31/2017956149N/A161N/A
9/30/2017934145N/A90N/A
6/30/2017872117N/A86N/A
3/31/201780996N/A41N/A
12/31/201676990N/A47N/A
9/30/201673179N/A81N/A
6/30/201667368N/A67N/A
3/31/201663965N/A77N/A
12/31/201564467N/A95N/A
9/30/201562667N/A100N/A
6/30/201562659N/A77N/A
3/31/201560045N/A75N/A
12/31/201455635N/A49N/A
9/30/201447622N/A33N/A
6/30/20143959N/A18N/A
3/31/201433512N/A17N/A
12/31/201327515N/A16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8279's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 8279's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 8279's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8279's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 8279's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8279's Return on Equity is forecast to be high in 3 years time


Discover growth companies